26
Participants
Start Date
November 30, 2015
Primary Completion Date
August 31, 2016
Study Completion Date
August 31, 2016
CD-LD IR
CD-LD IR containing 25 mg carbidopa and 100 mg levodopa
IPX203 180 mg
IPX203 containing 45 mg carbidopa and180 mg levodopa
IPX203 270 mg
IPX203 containing 67.5 mg carbidopa and 270 mg levodopa
Rytary 195 mg
Rytary 48.75Mg-195Mg Extended-Release Capsule
Rytary 145 mg
Rytary 36.25Mg-145Mg Extended-Release Capsule
Duke University Movement Disorders Clinic, Durham
Georgia Regents University, Augusta
Parkinson's Disease and Movement Disorders Center of Boca Raton, Boca Raton
University of South Florida Parkinson's Disease and Movement Disorder Center, Tampa
Collier Neurologic Specialists, Naples
University Hospitals Case Medical Center, Cleveland
QUEST Research Institute, Farmington Hills
Clinical Trials, Inc., Little Rock
Muhammad Ali Movement Disorder Center (MAMDC), Phoenix
The Parkinson's and Movement Disorder Institute, Fountain Valley
Premier Clinical Research, Spokane
Lead Sponsor
Impax Laboratories, LLC
INDUSTRY